Current Approaches for Personalized Therapy of Soft Tissue Sarcomas

Soft tissue sarcomas (STS) are a highly heterogeneous group of cancers of mesenchymal origin with diverse morphologies and clinical behaviors. While surgical resection is the standard treatment for primary STS, advanced and metastatic STS patients are not eligible for surgery. Systemic treatments, i...

Full description

Saved in:
Bibliographic Details
Published in:Complexity (New York, N.Y.) N.Y.), 2020, Vol.2020 (2020), p.1-15
Main Authors: Belitsky, Gennady A., Bokhyan, Beniamin Yu, Fetisov, Timur I., Lesovaya, Ekaterina A., Kirsanov, Kirill I., Yakubovskaya, Marianna G.
Format: Article
Language:English
Subjects:
Antimitotic agents
Antineoplastic agents
Cancer
Care and treatment
Chemical weapons
Chemotherapy
Chromosome translocations
Clinical trials
Congenital diseases
Drug development
Drug therapy, Combination
Drugs
Gene amplification
Genetic screening
Histology
Kinases
Ligands
Medical prognosis
Mesenchyme
Metastases
Metastasis
Molecular weight
Nilotinib
Patients
Phosphorylation
Review
Sarcoma
Surgery
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Soft tissue sarcomas (STS) are a highly heterogeneous group of cancers of mesenchymal origin with diverse morphologies and clinical behaviors. While surgical resection is the standard treatment for primary STS, advanced and metastatic STS patients are not eligible for surgery. Systemic treatments, including standard chemotherapy and newer chemical agents, still play the most relevant role in the management of the disease. Discovery of specific genetic alterations in distinct STS subtypes allowed better understanding of mechanisms driving their pathogenesis and treatment optimization. This review focuses on the available targeted drugs or drug combinations based on genetic aberration involved in STS development including chromosomal translocations, oncogenic mutations, gene amplifications, and their perspectives in STS treatment. Furthermore, in this review, we discuss the possible use of chemotherapy sensitivity and resistance assays (CSRA) for the adjustment of treatment for individual patients. In summary, current trends in personalized management of advanced and metastatic STS are based on combination of both genetic testing and CSRA.
ISSN:1076-2787
1357-714X
1099-0526
1369-1643
DOI:10.1155/2020/6716742